OralParenteralDosed ingredientTherapeutic flag Cosmetic cross-reference

Aminocaproic Acid

CAS 60-32-2

Aminocaproic Acid (CAS 60-32-2) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 220 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
7
SOURCE DrugCentral
Adverse signals
220
SOURCE IUPHAR/BPS
PubMed IDs
1
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Aminocaproic Acid
CAS Number
60-32-2
UNII
U6F3787206
InChIKey
SLXKOJJOQWFEFD-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1046
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
6-aminocaproic acidAmicar
dosed ingredientnatural productoralparenteraltherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1046 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 7 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 13691.78115942029 nM 69 -
- Potency 15628.285714285714 nM 26 -
- IC50 26650.873333333333 nM 2 -
- Kd 9000 nM 1 -
- Ki 50000 nM 1 -
Plasminogen
Enzyme
 IC50 4.4 - Homo sapiens
Tissue-type plasminogen activator
Enzyme
 INHIBITOR - - Homo sapiens
SOURCE DrugCentral 21 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Fear 60 201.115 10016275
Renal injury 55 183.112 10061481
Unevaluable event 71 167.988 10062355
Injury 73 163.947 10022116
Anhedonia 46 158.693 10002511
Emotional distress 53 140.821 10049119
Renal failure 73 98.115 10038435
Factor VIII inhibition 15 90.071 10048619
Multiple organ dysfunction syndrome 53 85.877 10077361
Anxiety 72 81.576 10002855
Stress 44 76.79 10042209
Renal impairment 49 61.581 10062237
Product dispensing error 23 59.372 10080359
Platelet count decreased 46 46.23 10035528
Medication error 29 43.768 10027091
Death 80 38.373 10011906
Epistaxis 32 38.241 10015090
Mouth haemorrhage 14 36.692 10028024
Haemorrhage 30 36.107 10055798
Haemarthrosis 10 29.071 10018829
Pain 79 27.738 10033371

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
plasminogen
PLG
 Binding 4.400000095367432 pIC50 24900876
SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
AMINOCAPROIC ACID 99 SU MTHSPL
Aminocaproic Acid 99 SU MTHSPL
6-aminocaproic acid 99 IN RXNORM
aminocaproic acid 99 SY RXNORM
Amicar 204292 BN RXNORM
SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Abdominal pain EACA LLT C0000737
Abdominal pain EACA PT C0000737
Agranulocytosis EACA LLT C0001824
Agranulocytosis EACA PT C0001824
Anaphylactic shock EACA LLT C0002792
Anaphylactic shock EACA PT C0002792
Anaphylactic shock EACA PT C0002792
Anaphylactoid reaction EACA LLT C0340865
Anaphylactoid reaction EACA PT C0340865
Blood creatine phosphokinase increased EACA PT C0853034
Blood urea increased EACA LLT C0151539
Blood urea increased EACA PT C0151539
Bradycardia EACA LLT C0428977
Bradycardia EACA PT C0428977
Cerebrovascular accident EACA LLT C0038454
Cerebrovascular accident EACA PT C0038454
Coagulopathy EACA LLT C0005779
Coagulopathy EACA PT C0005779
Confusional state EACA LLT C0009676
Confusional state EACA PT C0009676
Convulsion EACA LLT C0036572
Convulsion EACA PT C0036572
Creatine phosphokinase increased EACA LLT C0151576
Delirium EACA LLT C0011206
Delirium EACA PT C0011206
Dermatitis EACA PT C0011603
Diarrhoea EACA LLT C0011991
Diarrhoea EACA PT C0011991
Discomfort EACA PT C0234215
Dizziness EACA LLT C0012833
Dizziness EACA PT C0012833
Dizziness EACA PT C0012833
Dyspnoea EACA LLT C0013404
Dyspnoea EACA PT C0013404
Feeling abnormal EACA PT C1443060
Feeling abnormal EACA PT C1443060
Gastrointestinal pain EACA PT C0687713
Hallucination EACA LLT C0018524
Hallucination EACA PT C0018524
Headache EACA LLT C0018681
Headache EACA PT C0018681
Hypersensitivity EACA LLT C0020517
Hypersensitivity EACA PT C0020517
Hypotension EACA LLT C0020649
Hypotension EACA PT C0020649
Ill-defined disorder EACA PT C2047937
Injection site reaction EACA LLT C0151735
Injection site reaction EACA PT C0151735
Intracranial pressure increased EACA LLT C0151740
Intracranial pressure increased EACA PT C0151740
Lacrimation increased EACA PT C0152227
Leukopenia EACA LLT C0023530
Leukopenia EACA PT C0023530
Local reaction EACA LLT C0853813
Local reaction EACA PT C0853813
Loss of consciousness EACA PT C0041657
Malaise EACA LLT C0231218
Malaise EACA PT C0231218
Muscular weakness EACA LLT C0151786
Muscular weakness EACA PT C0151786
Musculoskeletal discomfort EACA PT C0948594
Myalgia EACA LLT C0231528
Myalgia EACA PT C0231528
Myopathy EACA LLT C0026848
Myopathy EACA PT C0026848
Myositis EACA LLT C0027121
Myositis EACA PT C0027121
Nasal congestion EACA LLT C0027424
Nasal congestion EACA PT C0027424
Nausea EACA LLT C0027497
Nausea EACA PT C0027497
Necrosis EACA LLT C0027540
Necrosis EACA PT C0027540
Oedema EACA LLT C0013604
Oedema EACA PT C0013604
Pain EACA LLT C0030193
Pain EACA PT C0030193
Peripheral ischaemia EACA LLT C0235490
Peripheral ischaemia EACA PT C0235490
Pruritus EACA LLT C0033774
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Aminocaproic Acid used for in pharmaceutical contexts?

Aminocaproic Acid (CAS 60-32-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Aminocaproic Acid?

Aminocaproic Acid has 220 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Fear, Renal injury, Unevaluable event, Injury, Anhedonia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Aminocaproic Acid also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for 6-Aminocaproic Acid with EU status "prohibited".

What clinical phase is Aminocaproic Acid in?

Aminocaproic Acid is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Aminocaproic Acid?

Aminocaproic Acid has 7 bioactivity rows in this page query. Rendered target entries include Plasminogen, Tissue-type plasminogen activator.